ACSL4 and Cognitive impairment: Inhibiting ACSL4 alleviated EBI‐SAH, evidenced by decreased inflammation, blood‐brain barrier (BBB) impairment, oxidative stress, brain edema, and behavioral and cognitive deficits, and increased the number of surviving neurons, indicating that ACSL4 exacerbated SAH‐induced EBI by mediating ferroptosis.[343]